ausbiz 8 February 2022
This Aussie MedTech is fast going global
Managing Director John Barrington AM kicks off with the startling statistic that the death rate from coronary disease is little changed in 50 years despite advances in medicine. Since listing late in 2021, John has been busy deploying the company strategy across the US, UK and Europe, and shares his insights into the recent December quarter update. The company's results of clinical trials and the roadmap to commercialisation of the algorithm will be announced to the market in due course.